Literatura - Netradiční způsoby podání farmak pro použití v anesteziologii a urgentní medicíně

1. BEVANS, T.; DEERING-RICE, C.; STOCKMANN, C.; LIGHT, A.; REILLY, C.;

SAKATA, D. J. Inhaled Remifentanil in Rodents. Anesthesia and Analgesia. 2016, 122(6), 1831-1838. ISSN 0003-2999. DOI: 10.1213/ANE.0000000000001228 2. BHARADWAJ, V. N.; TZABAZIS, A. Z.; KLUKINOV, M.; MANERING, N. A.;

YEOMANS, D. C. Intranasal Administration for Pain: Oxytocin and Other Polypeptides.

Pharmaceutics. 2021, 13(7),1088. ISSN 1999-4923. DOI:

10.3390/pharmaceutics13071088

3. CORRIGAN, M.; WILSON, S. S.; HAMPTON, J. Safety and efficacy of intranasally administered medications in the emergency department and prehospital settings.

American Journal of Health-System Pharmacy. 2015, 72(18), 1544-1554. ISSN 1079- 2082. DOI: 10.2146/ajhp140630

4. ČSN EN ISO 10993-10. Biologické hodnocení zdravotnických prostředků - Část 10:

Zkoušky na dráždivost a přecitlivělost oddáleného typu. Praha: Český normalizační institut, 2009.

5. ECKSTEIN, M.; SCHEELE, D.; WEBER, K.; STOFFEL-WAGNER, B.; MAIER, W.;

HURLEMANN, R. Oxytocin facilitates the sensation of social stress. Human Brain Mapping. 2014, 35(9), 4741-4750. ISSN 1065-9471. DOI: 10.1002/hbm.22508 6. EGAN, T. D. Remifentanil pharmacokinetics and pharmacodynamics. A preliminary

appraisal. Clinical Pharmacokinetics. 1995, 29(2), 80-94. ISSN 0312-5963. DOI:

10.2165/00003088-199529020-00003.

7. FDA. FDA announces preliminary assessment that certain naloxone products have the potential to be safe and effective for over-the-counter use [online]. FDA, 2022 [cit.

31.1.2023]. Dostupné z:https://www.fda.gov/news-events/press-announcements/fda- announces-preliminary-assessment-certain-naloxone-products-have-potential-be-safe- and-effective

8. FDA. Having Naloxone on Hand Can Save a Life During an Opioid Overdose [online].

FDA, 2019 [cit. 31.1.2023]. Dostupné z:https://www.fda.gov/consumers/consumer- updates/having-naloxone-hand-can-save-life-during-opioid-overdose

9. GOSSEN, A.; HAHN, A.; WESTPHAL, L.; PRINZ, S.; SCHULTZ, R. T.; GRUNDER, G.; SPRECKELMEYER, K. N. Oxytocin plasma concentrations after single intranasal oxytocin administration - a study in healthy men. Neuropeptides. 2012, 46(5), 211-215.

ISSN 0143-4179. DOI: 10.1016/j.npep.2012.07.001

10. GRIM, M.; NAŇKA, O.; HELEKAL, I. Atlas anatomie člověka II. Praha: Grada Publishing, 2017. ISBN 978-80-0904-3.

11. GUZMAN, Y. F.; TRONSON, N. C.; SATO, K.; MESIC, I.; GUEDEA, A. L.;

NISHIMORI, K.; RADULOVIC, J. Role ofoxytocin receptors in modulation of fear by social memory. Psychopharmacology. 2014, 231(10), 2097-2105. ISSN 0033-3158.

DOI: 10.1007/s00213-013-3356-6

12. HANSEN, M.S.; MATHIESEN, O.; TRAUTNER, S.; DAHL, J. B. Intranasal fentanyl in the treatment of acute pain--a systematic review. Acta Anaesthesiologica

Scandinavica. 2012, 56(4), 407-419. ISSN 0001-5172. DOI: 10.1111/j.1399- 6576.2011.02613.x

13. HAYASHIDA, M.; FUKUNAGA, A.; FUKUDA, K.; SAKURAI, S.; MAMIYA, H.;

ICHINOHE, T.; KANEKO, Y.; HANAOKA, K. The characteristics of intravenous adenosine-induced antinociception in a rabbit model of acute nociceptive pain: a comparative study with remifentanil. Anesthesia and Analgesia. 2006, 103(4), 1004- 1010, 2006. ISSN 0003-2999. DOI: 10.1213/01.ane.0000237306.05730.ea

14. HEINRICH, M.; BAUMGARTNER, T.; KIRSCHBAUM, C.; EHLERT, U. Social support and oxytocin interact to suppress cortisol and subjective responses to

psychosocial stress. Biological Psychiatry. 2003, 54(12), 1389-1398. ISSN 0006-3223.

DOI: 10.1016/s0006-3223(03)00465-7

15. HESHMATI, F.; NOROOZINIA, H.; ABBASIVASH, R.; MAHOORI, A.; GHARAEE, H. Intranasal sufentanil for postoperative pain control in lower abdominal pediatric surgery. Iranian Journal of Pharmacology and Therapeutics. 2006, 5(2), 131-133. ISSN 1735-2657.

16. HESS, L.; MÁLEK, J.; KURZOVÁ, A., JAČEK, M.; MATĚJČKOVÁ, J.; VOTAVA, M. Conjunctival administration of buprenorphine in rabbits. Pain Practice. 2012, 12(S1), 19-20. ISSN 1530-7085.

17. HESS, L.; MÁLEK, J. Netradiční způsoby aplikace anestetik. Možnosti jejich využití v urgentní medicíně a medicíně katastrof. Praha: Karolinum, 2016.

ISBN 9788024634500

18. HESS, L.; VOTAVA, M.; MÁLEK, J.; KURZOVÁ, A.; SLÍVA, J. Sedative effects of intranasal oxytocin in rabbits and rhesus monkeys. Physiological Research. 2016, 65(Suppl 4), S473-S480. ISSN 0862-8408. DOI: 10.33549/physiolres.933513 19. HUANG, H.; MICHETTI, C.; BUSNELLI, M.; MANAGO, F.; SANNINO, S.;

SCHEGGIA, D.; GIANCARDO, L.; SONA, D.; MURINO, V.; CHINI, B.;

SCATTONI, M. L.; PAPALEO, F. Chronic and acute intranasal oxytocin produce divergent social effects in mice. Neuropsychopharmacology. 2014, 39(5), 1102-1114.

ISSN 0893-133X. DOI: 10.1038/npp.2013.310

20. INTRANASAL.NET. Therapeutic Intranasal Drug Delivery: Needleless treatment options for medical problems [online]. intranasal.net, 1999 [cit. 31.1.2023]. Dostupné z:

http://www.intranasal.net/Home/default.htm

21. KIMURA, T.; TANIZAWA, O.; MORI, K.; BROWNSTEIN, M. J.; OKAYAMA, H.

Structure and expression of a human oxytocin receptor. Nature. 1992, 356(6369), 526- 529. ISSN 0028-0836. DOI: 10.1038/356526a0

22. KNOBLOCH, H. S.; GRINEVICH, V. Evolution of oxytocin pathways in the brain of vertebrates. Frontiers in Behavioral Neuroscience. 2014, 8(February), 31. ISSN 1662- 5153. DOI: 10.3389/fnbeh.2014.00031

23. KNOBLOCH, H. S.; CHARLET, A.; HOFFMANN, L. C.; ELIAVA, M.; KHRULEV, S.; CETIN, A. H.; OSTEN, P.; SCHWARZ, M. K.; SEEBURG, P. H.; STOOP, R.;

GRINEVICH, V. Evoked axonal oxytocin release in the central amygdala attenuates fear response. Neuron. 2012, 73(3), 553-566. ISSN 0896-6273. DOI:

10.1016/j.neuron.2011.11.030

24. KNOR, J.; MÁLEK, J. Farmakoterapie urgentních stavů: průvodce léčbou život ohrožujících stavů. 3. dopl. a rozšíř. vyd. Praha: Maxdorf, 2019. Moderní

farmakoterapie; Jessenius. ISBN 978-80-7345-595-8.

25. KUNDRA, A.; HEARD, C.; GARDNER, T.; WANAMAKER, C.; CIAMBELLA, C.

Intranasal Remifentanil as an Adjunct to Oral Midazolam Sedation in Pediatric Dental

Patients. Journal of Anesthesiology & Intensive Care Medicine. 2017, 3(4), 555618.

ISSN 2474-7653. DOI: 10.19080/JAICM.2017.03.555618

26. LEE, M. R.; SHNITKO, T. A.; BLUE, S. W.; KAUCHER, A. V.; WINCHELL, A. J.;

ERIKSON, D. W.; GRANT, K. A.; LEGGIO, L. Labeled oxytocin administered via the intranasal route reaches the brain in rhesus macaques. Nature Communication. 2020, 11(1), 2783. ISSN 2041-1723. DOI: 10.1038/s41467-020-15942-1

27. LYNN, R. R.; GALINKIN, J. L. Naloxone dosage for opioid reversal: current evidence and clinical implications. Therapeutic Advances in Drug Safety. 2018, 9(1), 63-88.

ISSN 2042-0986. DOI: 10.1177/2042098617744161

28. MACDONALD, E.; DADDS, M. R.; BRENNAN, J. L.; WILLIAMS, K.; LEVY, F.;

CAUCHI, A. J. A review of safety, sideeffects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology. 2011, 36(8), 1114-1126. ISSN 0306-4530. DOI: 10.1016/j.psyneuen.2011.02.015

29. MACDONALD, K.; FEIFEL, D. Oxytocin's role in anxiety: a critical appraisal. Brain Research. 2014, 1580(September), 22-56. ISSN 0006-8993. DOI:

10.1016/j.brainres.2014.01.025

30. MANJUSHREE, R.; LAHIRI, A.; GHOSH, B. R.; LAHA, A.; HANDA, K. Intranasal fentanyl provides adequate postoperative analgesia in pediatric patients. Canadian Journal of Anaesthesia. 2002, 49(2), 190-193. ISSN 0832-610X. DOI:

10.1007/BF03020494

31. MICHELSEN, L. G.; HUG-jr., C. C. The pharmacokinetics of remifentanil. Journal of Clinical Anesthesia. 1996, 8(8), 679-682. ISSN 0952-8180. DOI: 10.1016/s0952- 8180(96)00179-1

32. MODI, M. E.; CONNOR-STROUD, F.; LANDGRAF, R.; YOUNG, L. J.; PARR, L. A.

Aerosolized oxytocin increases cerebrospinal fluid oxytocin in rhesus macaques.

Psychoneuroendocrinology. 2014, 45(July), 49-57. ISSN 0306-4530. DOI:

10.1016/j.psyneuen.2014.02.011

33. MYVMC. Anatomy and physiology of the nasal cavity (inner nose) and mucosa [online]. myVMC, 2012 [cit. 31.1.2023]. Dostupné z:

https://www.myvmc.com/medical-centres/lungs-breathing/anatomy-and-physiology-of- the-nasal-cavity-inner-nose-and-mucosa/

34. PARR, L. A.; MODI, M.; SIEBERT, E.; YOUNG, L. J. Intranasal oxytocin selectively attenuates rhesus monkeys' attention to negative facial expressions.

Psychoneuroendocrinology. 2013, 38(9), 1748-1756. ISSN 0306-4530. DOI:

10.1016/j.psyneuen.2013.02.011

35. PROMMER, E.; THOMPSON, L. Intranasal fentanyl for pain control: current status with a focus on patient considerations. Patient Preference and Adherence. 2011, 5(March), 157-164. ISSN 1177-889X. DOI: 10.2147/PPA.S7665

36. RING, R. H.; MALBERG, J. E.; POTESTIO, L.; PING, J.; BOIKESS, S.; LUO, B.;

SCHECHTER, L. E.; RIZZO, S.; RAHMAN, Z.; ROSENZWEIG-LIPSON, S.

Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology, 2006, 185(2), 218-225. ISSN 0033- 3158. DOI: 10.1007/s00213-005-0293-z

spc&as=calypsol-spc

Dostupné z:

https://www.sukl.cz/modules/medication/download.php?file=SPC185185.pdf&type=sp c&as=fentanyl-torrex-spc

https://www.sukl.cz/modules/medication/download.php?file=SPC154065.pdf&type=sp c&as=naloxone-wzf-polfa-spc

https://www.sukl.cz/modules/medication/download.php?file=SPC165439.pdf&type=sp c&as=oxytocin-avmc-spc

https://www.sukl.cz/modules/medication/download.php?file=SPC190640.pdf&type=sp c&as=remifentanil-b-braun-spc

Dostupné

z: https://www.sukl.cz/modules/medication/download.php?file=SPC166249.pdf&type=

spc&as=sufentanil-torrex-spc

43. ŠLAPÁK, I; JANEČEK, D.; LAVIČKA, L. Klinická anatomie a fyziologie nosu. In:

Základy otorinolaryngologie a foniatrie pro studenty speciální pedagogiky [online].

Brno: Klinika dětské ORL Lékařské fakulty MU a Fakultní Nemocnice Brno, 2009 [cit.

31.1.2023]. Dostupné z:

https://is.muni.cz/elportal/estud/pedf/js09/orl/web/pages/2_1_klinicka_anatomie_a_fyzi ologie_nosu.html.

44. TANAKA, A.; FURUBAYASHI, T.; ARAI, M.; INOUE, D.; KIMURA, S.;

KIRIYAMA, A.; KUSAMORI, K.; KATSUMI, H.; YUTANI, R.; SAKANE, T.;

YAMAMOTO, A. Delivery of Oxytocin to the Brain for the Treatment of Autism Spectrum Disorder by Nasal Application. Molecular Pharmaceutics. 2018, 15(3), 1105- 1111. DOI: 10.1021/acs.molpharmaceut.7b00991

45. TELEFLEX. Intranasální rozprašovací aplikátor MAD Nasal* [online]. Teleflex inc.,

46. THAKKER, A., SHANBAG, P. A randomized controlled trial of intranasal-midazolam versus intravenous-diazepam for acute childhood seizures. Journal of Neurology. 2013, 260(2), 470-474. ISSN 0340-5354. DOI: 10.1007/s00415-012-6659-3

47. VERGHESE, S. T., HANNALLAH, R. S., BRENNAN, M., YARVITZ, J. L., HUMMER, K. A., PATEL, K. M., HE, J., MCCARTER, R. The effect of intranasal administration of remifentanil on intubating conditions and airway response after

sevoflurane induction of anesthesia in children. Anesthesia and Analgesia. 2008, 107(4), 1176-1181. ISSN 0003-2999. DOI: 10.1213/ane.0b013e3181838e95

48. WALDHERR, M.; NEUMANN, I. D. Centrally released oxytocin mediates mating- induced anxiolysis in male rats. Proceedings of the National Academy of Sciences of the United States of America. 2007, 104(42), 16681-16684. ISSN 0027-8424. DOI:

10.1073/pnas.0705860104

49. YEOMANS, D. C.; HANSON, L. R.; CARSON, D. S.; TUNSTALL, B. J.; LEE, M. R.;

TZABAZIS, A. Z.; JACOBS, D.; FREY, W. H. Nasal oxytocin for the treatment of psychiatric disorders and pain: achieving meaningful brain concentrations.

Translational Psychiatry. 2021, 11(1), 388. ISSN 2158-3188. DOI: 10.1038/s41398- 021-01511-7

No documento Netradiční způsoby podání farmak pro použití v anesteziologii a urgentní medicíně (páginas 33-40)